Form 4: ADPT CSO Sells 10,000 Shares Under 10b5-1 Plan

Adaptive Biotechnologies' Chief Scientific Officer, Harlan S. Robins, sold 10,000 shares of common stock for a weighted average price of $14.82 per share.

Summary

• Harlan S. Robins, Chief Scientific Officer of Adaptive Biotechnologies Corp (ADPT), reported a sale of common stock.
• The transaction involved the disposition of 10,000 shares of common stock.
• The shares were sold on November 10, 2025, at a weighted average price of $14.82 per share.
• The sale was executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robins on August 11, 2025.
• Following this transaction, Mr. Robins beneficially owns 1,269,524 shares of common stock directly.

Sentiment

Score: 4

Explanation: The filing reports an insider sale of common stock by a Chief Scientific Officer. While executed under a pre-arranged 10b5-1 plan, insider selling can be perceived as a slight negative signal, though less so than unscheduled sales, as it often relates to personal financial planning rather than a change in company outlook.

Negatives

• The Chief Scientific Officer sold 10,000 shares of company stock, which reduces insider ownership.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This insider transaction report does not provide specific details to analyze broader industry trends or competitor actions.

Stakeholder Impact

• Shareholders may note the reduction in direct ownership by a key executive, which could be interpreted in various ways depending on individual investment philosophies.

Key Dates

Keywords

ADPT, Adaptive Biotechnologies, Harlan S. Robins, Chief Scientific Officer, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan